Affiliation:
1. Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2. Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Background
Autonomic dysfunction (AD) is one of the non-motor features of Parkinson’s disease (PD). Some symptoms tend to occur in the early stages of PD. AD also has a great impact on patient’s quality of life. In this study, we aimed to discover the association between AD (Scales for Outcomes in Parkinson’s disease-Autonomic, SCOPA-AUT) and microstructural changes in white matter tracts in drug-naïve early PD patients to elucidate the central effects of autonomic nervous system impairments.
Method
In total, this study included 85 subjects with PD recruited from the Parkinson’s Progression Markers Initiative (PPMI) database. Among the 85 PD patients, 38 were in Hoehn & Yahr stage 1 (HY1PD) and 47 were in stage 2 (HY2PD). Diffusion magnetic resonance imaging (DMRI) data were reconstructed in the MNI space using q-space diffeomorphic reconstruction to obtain the spin distribution function. The spin distribution function (SDF) values were used in DMRI connectometry analysis. We investigated through diffusion MRI connectometry the structural correlates of white matter tracts with SCOPA-AUT subscores and total score.
Results
Connectometry analysis also revealed positive association with white matter density in bilateral corticospinal tract in HY1PD patients and negative association in genu of corpus callosum (CC) and, bilateral cingulum in both groups. In addition, there were associations between gastrointestinal, sexual, thermoregulatory and urinary items and structural brain connectivity in PD.
Conclusion
Our study reveals positive correlation, suggesting neural compensations in early PD. Cingulum and CC tracts have well-known roles in PD pathology, compatible with our findings that bring new insights to specific areas of AD and its role in central nervous system (CNS) neurodegeneration, paving the way for using prodromal makers in the diagnosis and treatment of PD.
Funder
Michael J. Fox Foundation for Parkinson’s Research
W Garfield Weston Foundation
Alzheimer’s Association
Canadian Institutes for Health Research
Natural Sciences and Engineering Research Council of Canada
Parkinsons Progression Markers Initiative (PPMI)
AbbVie, Avid Radiopharmaceuticals, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline (GSK)
Pfizer, Piramal Imaging, Roche, Servier, and UCB
Eli Lilly and Company, Lundbeck, Merck, Meso Scale Discovery (MSD)
Subject
General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献